RxDoctor Payments DataLook up a doctor →

Alfredo Renzo Arauco Brown, MD

Pulmonary Disease · Weslaco, TXNPI 1841503513

Payments from drug & device makers

$816,835in general payments, 2019–2025

Across 264 payments — averaging $3094.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$737K
  • Mylan Specialty L.p.$34K
  • Boehringer Ingelheim$23K
  • AstraZeneca$11K
  • Boehringer Ingelheim International GmbH$8K
  • Intuitive Surgical$3K
  • plus $1K from 10 others
$21,324in research payments, 2019–2025

Across 9 payments — averaging $2369.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$20K
  • United Therapeutics Corporation$1K

What the payments were for

  • Food & beverage$2,24146%
  • Education$2,59654%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$816,835 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$182,405
Medicare patients
365
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate94$1,118,965
Tyvaso DpiTreprostinil23$608,162
AdempasRiociguat15$211,315
Orenitram ErTreprostinil Diolamine26$186,877
OpsumitMacitentan12$153,841
Trelegy ElliptaFluticasone/Umeclidin/Vilanter164$148,845
ZemairaAlpha-1-Proteinase Inhibitor15$118,581
Dupixent PenDupilumab16$57,962
Breo ElliptaFluticasone/Vilanterol98$43,266
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$29,598
Pirfenidone24$20,703
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$10,978
SymbicortBudesonide/Formoterol Fumarate42$9,392
Albuterol Sulfate HfaAlbuterol Sulfate276$7,121
Advair DiskusFluticasone Propion/Salmeterol20$6,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$22,950$1,118,96594 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$17$221,710314 claims
Actelion Pharmaceuticals US, Inc.Opsumit$39$153,84112 claims
AstraZenecaBreztri Aerosphere, Symbicort$10,502$20,36954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Weslaco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →